Latest Tax Rebates News

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

AnteoTech Ltd has received a $2.59 million cash rebate from the Australian Tax Office for its 2025 R&D activities, underscoring the success of its recent strategic initiatives.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

South Harz Potash Limited has bolstered its balance sheet through a combined A$2.39 million equity raise, positioning itself to pursue a dual-asset strategy targeting new critical minerals while preserving its core German potash project.

Micro-X has landed a significant supply agreement with a top US healthcare provider for its Rover Plus mobile X-ray units, while progressing clinical trials and development milestones for its innovative CT imaging products.

Cobre Limited reports strong metallurgical results from its Botswana copper projects alongside a successful AU$1.68 million capital raising, setting the stage for upcoming resource estimates and environmental approvals.

Lincoln Minerals has identified multiple high-priority drill targets at its Minbrie Copper-Base Metals Project with drilling planned for late 2025, while its Kookaburra Graphite Project achieves battery-grade purity, underscoring the company’s strategic positioning in critical minerals.

Mont Royal Resources is progressing its merger with Commerce Resources to create a dual-listed Canadian critical metals developer, combining rare earth and lithium assets in Quebec.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

AnteoTech advances its battery technology with a new US joint development agreement and achieves significant performance milestones, while restructuring to sharpen its commercial focus.